September 2022. Volume 18. Number 3

Benefits of triple therapy for cystic fibrosis in patients heterozygous for Phe508del with another added mutation

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Barry PJ, Mall MA, Álvarez A, Colombo C, de Winter-de Groot KM, Fajac I, et al. Triple Therapy for Cystic Fibrosis Phe508del-Gating and Residual Function Genotypes. N Engl J Med. 2021; 385:815-25.

Reviewers: Cabrera Morente L1, Molina Arias M2.
1CS San Felipe. Distrito Sanitario de Jaén. Jaén. España.
2Servicio de Gastroenterología. Hospital Infantil Universitario La Paz. Madrid. España.
Correspondence: Laura Cabrera Morente. Email: lauramorente@hotmail.com
Reception date: 29/08/2022
Acceptance date: 07/09/2022
Publication date: 21/09/2022

Abstract

Authors´conclusions: triple therapy is effective and safe in patients with Phe508del genotypes and another added mutation, providing an additional benefit compared to previous treatments.

Reviewers´commentary: triple therapy appears to be safe and more effective than dual treatment with modulators, although studies assessing results of greater clinical relevance would be needed.

How to cite this article

Cabrera Morente l, Molina Arias M. Beneficio de la triple terapia en fibrosis quística con hetero-cigosis F508del y otra mutación adicional. Evid Ped. 2022;18:22.

AVC | Critically appraised articles

Barry PJ, Mall MA, Álvarez A, Colombo C, de Winter-de Groot KM, Fajac I, et al. Triple Therapy for Cystic Fibrosis Phe508del-Gating and Residual Function Genotypes. N Engl J Med. 2021; 385:815-25.

Reviewers: Cabrera Morente L1, Molina Arias M2.
1CS San Felipe. Distrito Sanitario de Jaén. Jaén. España.
2Servicio de Gastroenterología. Hospital Infantil Universitario La Paz. Madrid. España.
Correspondence: Laura Cabrera Morente. Email: lauramorente@hotmail.com
Reception date: 29/08/2022
Acceptance date: 07/09/2022
Publication date: 21/09/2022

How to cite this article

Cabrera Morente l, Molina Arias M. Beneficio de la triple terapia en fibrosis quística con hetero-cigosis F508del y otra mutación adicional. Evid Ped. 2022;18:22.

21/09/2022

Linked Comment